Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
ConditionAdvanced Prostate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity Health Network, Toronto
About this trial
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.
Eligibility criteria
Qualifiers
Male, age ≥ 18 years
Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
Poor risk patients with mCSPC at study enrollment
De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
Disqualifiers
Under a randomized-controlled trial with unknown allocation of systemic therapy
Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
Unable to provide written consent by patient and their legal representatives
conditions which would significantly impair the patient's ability to comply with study procedures and follow up
Trial design
Treatments tested in this trial
- Ga 68 PSMA-11 PET
- 18F-DCFPyL PET
- FDG PET
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov